

Boris Kovacic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2944757/publications.pdf>

Version: 2024-02-01

25
papers

1,681
citations

394421

19
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

2720
citing authors

#	ARTICLE	IF	CITATIONS
1	STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. <i>Oncogene</i> , 2021, 40, 1091-1105.	5.9	42
2	DRUGPATH – a novel bioinformatic approach identifies DNA-damage pathway as a regulator of size maintenance in human ESCs and iPSCs. <i>Scientific Reports</i> , 2019, 9, 1897.	3.3	5
3	Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. <i>Nature Immunology</i> , 2017, 18, 293-302.	14.5	191
4	Full biological characterization of human pluripotent stem cells will open the door to translational research. <i>Archives of Toxicology</i> , 2016, 90, 2173-2186.	4.2	7
5	Clinical impact of studying epithelial–mesenchymal plasticity in pluripotent stem cells. <i>European Journal of Clinical Investigation</i> , 2015, 45, 415-422.	3.4	3
6	elF3 controls cell size independently of S6K1-activity. <i>Oncotarget</i> , 2015, 6, 24361-24375.	1.8	13
7	Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. <i>Leukemia</i> , 2014, 28, 1918-1922.	7.2	12
8	Lactotransferrin-Cre reporter mice trace neutrophils, monocytes/macrophages and distinct subtypes of dendritic cells. <i>Haematologica</i> , 2014, 99, 1006-1015.	3.5	15
9	Authentication of Primordial Characteristics of the CLBL-1 Cell Line Prove the Integrity of a Canine B-Cell Lymphoma in a Murine In Vivo Model. <i>PLoS ONE</i> , 2012, 7, e40078.	2.5	21
10	Diverging fates of cells of origin in acute and chronic leukaemia. <i>EMBO Molecular Medicine</i> , 2012, 4, 283-297.	6.9	22
11	Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis. <i>Cell</i> , 2011, 147, 306-319.	28.9	122
12	The cooperating mutation or –second hit– determines the immunologic visibility toward MYC-induced murine lymphomas. <i>Blood</i> , 2011, 118, 4635-4645.	1.4	30
13	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. <i>Blood</i> , 2010, 116, 1548-1558.	1.4	56
14	Stat5 is indispensable for the maintenance of <i>bcr/abl</i> –positive leukaemia. <i>EMBO Molecular Medicine</i> , 2010, 2, 98-110.	6.9	206
15	Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. <i>Blood</i> , 2008, 111, 4511-4522.	1.4	101
16	Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. <i>Blood</i> , 2008, 112, 3878-3888.	1.4	87
17	The different functions of Stat5 and chromatin alteration through Stat5 proteins. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6237.	3.0	39
18	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. <i>Blood</i> , 2007, 109, 1678-1686.	1.4	108

#	ARTICLE	IF	CITATIONS
19	Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metalloproteinase Induction. <i>Neoplasia</i> , 2007, 9, 279-291.	5.3	117
20	Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. <i>Blood</i> , 2006, 107, 4898-4906.	1.4	192
21	STAT1 acts as a tumor promoter for leukemia development. <i>Cancer Cell</i> , 2006, 10, 77-87.	16.8	136
22	Clusterin Regulates Drug-Resistance in Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1300-1307.	0.7	41
23	TYK2 is a key regulator of the surveillance of B lymphoid tumors. <i>Journal of Clinical Investigation</i> , 2004, 114, 1650-1658.	8.2	50
24	TYK2 is a key regulator of the surveillance of B lymphoid tumors. <i>Journal of Clinical Investigation</i> , 2004, 114, 1650-1658.	8.2	32
25	Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. <i>Blood</i> , 2003, 101, 4937-4943.	1.4	33